Related Experiment Video
Updated: Jul 22, 2026

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
Published on: March 28, 2018
Primary sclerosing cholangitis: a long-term follow-up study.
E Aadland1, E Schrumpf, O Fausa
1Medical Dept. A, Rikshospitalet, University of Oslo, Norway.
Primary sclerosing cholangitis (PSC) patients diagnosed between 1975-1984 showed a reduced life expectancy by approximately 30 years. Liver disease progression was minimal in survivors, but severe necrosis correlated with mortality.
Area of Science:
- Hepatology
- Gastroenterology
- Immunology
Background:
- Primary sclerosing cholangitis (PSC) is a chronic liver disease often associated with inflammatory bowel disease (IBD).
- The long-term prognosis and disease progression patterns in PSC patients require further elucidation.
- Understanding PSC's impact on survival is crucial for patient management.
Purpose of the Study:
- To assess the long-term outcomes and survival rates of patients diagnosed with primary sclerosing cholangitis.
- To evaluate the progression of liver disease and associated histological changes in PSC patients.
- To compare the life expectancy of PSC patients with the general population.
Main Methods:
- Retrospective analysis of 45 PSC patients diagnosed between 1975 and 1984.
- Follow-up study in 1985 including clinical examination, laboratory tests (transaminases, alkaline phosphatases, bilirubin), cholangiography, and liver biopsy.
- Survival analysis comparing PSC patients to a general population cohort.
Main Results:
- Twelve out of 45 PSC patients died (26.7%), primarily from PSC-related causes.
- In surviving patients, clinical and biochemical markers showed no significant liver disease progression; cholangiography indicated mild progression in only 3 patients.
- Liver biopsy findings correlated with clinical course: portal inflammation and fibrosis in benign cases, widespread piecemeal necrosis in those who deteriorated.
- The 50% survival post-diagnosis was 17 years for PSC patients versus 50 years for the general population, indicating a ~30-year reduction in life expectancy.
Conclusions:
- Primary sclerosing cholangitis significantly reduces life expectancy by approximately 30 years.
- While liver disease progression may be slow in some PSC patients, histological findings like piecemeal necrosis are critical indicators of poor prognosis.
- Association with inflammatory bowel disease is universal in PSC, underscoring the systemic nature of the condition.
More Related Videos
04:02Laparoscopic Cholecystectomy with Indocyanine Green Fluorescence: Choledochoscopic Stone Extraction and Primary Duct Suture
Published on: November 25, 2025
05:22Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma
Published on: February 13, 2026
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Chronic Pancreatitis II: Pathophysiology